careCycle vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
careCycle is a healthcare platform that helps patients navigate post-acute care transitions — discharge planning, home health coordination, and care management after hospital stays. HQ: San Francisco.
About
careCycle is a care transition and post-acute care management platform designed to improve patient outcomes and reduce readmissions following hospital discharge. The company's technology helps care coordinators, discharge planners, and case managers navigate the complex process of transitioning patients from hospital to the next level of care — home health agencies, skilled nursing facilities, rehabilitation centers, or structured home care programs. Post-discharge coordination failures are a major driver of hospital readmissions, which cost the U.S. healthcare system approximately $26 billion annually.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.